1. Home
  2. NUVL vs PRIM Comparison

NUVL vs PRIM Comparison

Compare NUVL & PRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.40

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Logo Primoris Services Corporation

PRIM

Primoris Services Corporation

HOLD

Current Price

$94.45

Market Cap

6.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
PRIM
Founded
2017
1960
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Water Sewer Pipeline Comm & Power Line Construction
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.7B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
NUVL
PRIM
Price
$123.40
$94.45
Analyst Decision
Strong Buy
Buy
Analyst Count
16
15
Target Price
$134.75
$155.20
AVG Volume (30 Days)
2.5M
1.9M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
0.19%
EPS Growth
N/A
51.66
EPS
N/A
0.32
Revenue
N/A
N/A
Revenue This Year
N/A
$9.92
Revenue Next Year
$1,239.49
$8.80
P/E Ratio
N/A
$324.72
Revenue Growth
N/A
N/A
52 Week Low
$71.14
$71.97
52 Week High
$123.62
$205.50

Technical Indicators

Market Signals
Indicator
NUVL
PRIM
Relative Strength Index (RSI) 66.60 31.60
Support Level $97.71 N/A
Resistance Level N/A $140.80
Average True Range (ATR) 4.37 9.00
MACD 1.97 -0.90
Stochastic Oscillator 99.39 1.11

Price Performance

Historical Comparison
NUVL
PRIM

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About PRIM Primoris Services Corporation

Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.

Share on Social Networks: